A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors

Summary

This is a Phase 1/2, multi-regional, multi-center, open-label, first-in-human (FIH), dose-escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary clinical activity of AP402 in HER2-positive patients with locally or advanced solid tumors.

Timeline

Start

2025-04-22

Primary completion

2026-12-01

Completion

2027-12-01

Drugs

Indications